Stem Cell Therapeutics shares blitzed after PhIIb stroke trial fails

Shares of Stem Cell Therapeutics melted away to mere pennies this morning after the developer announced that its troubled Phase IIb trial for its new stroke therapy ended in failure after researchers were done in by a high placebo response. In a release out this morning the company reported that their Phase IIb clinical trial of NTx-265 in acute stroke "showed that there was substantial improvement in the primary endpoint absolute change in NIHSS in both placebo treated patients and those...